Enhabit, Inc. (NYSE:EHAB) Director Buys $34,760.00 in Stock

Enhabit, Inc. (NYSE:EHAB) Director Jeffrey Bolton purchased 4,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $8.69 per share, with a total value of $34,760.00. Following the purchase, the director now owns 98,144 shares of the company’s stock, valued at approximately $852,871.36. The trade was a 4.25 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Enhabit Trading Down 0.1 %

Shares of NYSE EHAB traded down $0.01 during mid-day trading on Thursday, hitting $8.52. The stock had a trading volume of 224,440 shares, compared to its average volume of 573,122. The business has a 50 day moving average price of $7.52 and a two-hundred day moving average price of $8.31. Enhabit, Inc. has a 1 year low of $6.85 and a 1 year high of $11.74. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The firm has a market cap of $428.42 million, a P/E ratio of -3.68 and a beta of 1.89.

Enhabit (NYSE:EHAB) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The firm had revenue of $253.60 million during the quarter, compared to analysts’ expectations of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same quarter in the previous year, the firm posted $0.03 EPS. On average, equities analysts anticipate that Enhabit, Inc. will post 0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Enhabit

Several institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its holdings in shares of Enhabit by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 37,950 shares of the company’s stock valued at $443,000 after acquiring an additional 2,078 shares in the last quarter. Gladius Capital Management LP bought a new position in Enhabit in the 2nd quarter worth $31,000. SummerHaven Investment Management LLC lifted its position in shares of Enhabit by 2.8% in the 2nd quarter. SummerHaven Investment Management LLC now owns 61,508 shares of the company’s stock worth $549,000 after purchasing an additional 1,660 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Enhabit by 1.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 400,575 shares of the company’s stock valued at $3,573,000 after purchasing an additional 5,936 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Enhabit by 1,119.6% during the second quarter. Allspring Global Investments Holdings LLC now owns 45,832 shares of the company’s stock valued at $409,000 after buying an additional 42,074 shares during the period.

Analyst Ratings Changes

EHAB has been the topic of a number of research reports. Leerink Partners reissued a “market perform” rating and set a $8.00 price objective (down from $8.50) on shares of Enhabit in a report on Tuesday, November 19th. Jefferies Financial Group upgraded shares of Enhabit from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $8.25 to $9.50 in a report on Monday. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $9.40.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.